{
    "Trade/Device Name(s)": [
        "Elecsys proBNP II",
        "Elecsys proBNP II STAT"
    ],
    "Submitter Information": "Roche Diagnostics",
    "510(k) Number": "K223637",
    "Predicate Device Reference 510(k) Number(s)": [
        "K210546"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBC"
    ],
    "Summary Letter Date": "June 20, 2023",
    "Summary Letter Received Date": "June 21, 2023",
    "Submission Date": "November 30, 2022",
    "Regulation Number(s)": [
        "21 CFR 862.1117"
    ],
    "Regulation Name(s)": [
        "B-type natriuretic peptide test system"
    ],
    "Analyte Class(es)": [
        "chemistry",
        "endocrine"
    ],
    "Analyte(s)": [
        "N-terminal pro-Brain natriuretic peptide (NT-proBNP)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "cobas e 601",
        "cobas e immunoassay analyzers"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemiluminescence immunoassay (ECLIA)"
    ],
    "Methodologies": [
        "Sandwich immunoassay",
        "Quantitative measurement"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Elecsys proBNP II and Elecsys proBNP II STAT assays for quantitative NT-proBNP measurement on cobas e immunoassay analyzers.",
    "Indications for Use Summary": "Immunoassay for in vitro quantitative determination of NT-proBNP in human serum and plasma as an aid in diagnosis of suspected heart failure, acute decompensated heart failure (ADHF) in emergency patients, risk stratification in acute coronary syndrome and heart failure, and assessment of cardiovascular event risk in patients with stable coronary artery disease.",
    "fda_folder": "Clinical Chemistry"
}